Rochester Medical Corp (NASDAQ:ROCM)

CAPS Rating: 3 out of 5

Develops, manufactures and markets a line of innovative, technologically enhanced PVC-free and latex-free urinary continence and urine drainage care products for the extended care and acute care markets.

Results 1 - 20 of 52 : 1 2 3 Next »

Recs

0
Member Avatar adnanfakhouri (< 20) Submitted: 2/19/2013 5:56:17 PM : Outperform Start Price: $14.12 ROCM Score: +11.93

Hi

Recs

0
Member Avatar Ahjusshi (< 20) Submitted: 5/1/2012 9:52:24 PM : Outperform Start Price: $10.10 ROCM Score: +56.05

Positive cash flow, increasing earnings, and no long term debt.

Recs

0
Member Avatar laserfocus (< 20) Submitted: 3/9/2012 12:14:14 PM : Outperform Start Price: $9.86 ROCM Score: +58.68

ROCM investment in building its sales team has been made, so top line growth will begin falling the bottom line in the coming quarters.

Recs

0
Member Avatar kayceygirl (84.48) Submitted: 8/14/2010 1:37:00 AM : Outperform Start Price: $8.99 ROCM Score: +37.80

This is one of my STARZ.
Here is the thought process on this STAR:
a) Divided rate over Zero
b) 3 Year Beta between -5 & +3
c) 15% + Insider ownership
d) No greater than -50% Growth rate for the last 3 years (tough last couple of years so good that insiders are still owning the stocks)
e) Current CAPS rating between 3 Stars & 5 Stars
Open to all Industries and Sectors screened this down to just 250 stocks. I like round numbers. 12 of them I already own through other screening tools. I tend to be somewhat conservative but looking for 3 things at this point in my investing:
1. Stability & Strength
2. Yield and Modest Growth
3. Strong Position within a sector regardless of whether the
entire sector is strong or not. Each sector has to perform to some degree for the whole world economy to function. I am looking for 5 or more years down the road, ROI, and Growth. Not looking for rockets, just stars. This is a Star!!

Recs

0
Member Avatar pbtoau78 (75.65) Submitted: 4/9/2010 10:56:23 AM : Outperform Start Price: $12.85 ROCM Score: -11.21

Potential buyout target

Recs

0
Member Avatar biovestor (< 20) Submitted: 6/28/2008 6:41:36 AM : Outperform Start Price: $10.62 ROCM Score: +28.10

Medical device maker with innovative, anti-infective Foley catheter, $3/share in cash, and pending litigation with Covidien that could result in cash windfall based on previous settlements with C.R. Bard and others.

Recs

0
Member Avatar najdar (< 20) Submitted: 4/30/2008 3:07:15 AM : Outperform Start Price: $11.89 ROCM Score: +20.56

tpx

Recs

0
Member Avatar krokarefur (< 20) Submitted: 4/25/2008 3:10:47 PM : Outperform Start Price: $12.70 ROCM Score: +9.86

For a user of their key product it is very valuable to get 200 free a month in stead of 4. (1st. of April press release!)

I do not say that they will be using 50x more but maby 15X. The stock must get a nice take of again.

Recs

0
Member Avatar RUFFOPTIONS (< 20) Submitted: 4/3/2008 2:48:51 PM : Outperform Start Price: $11.64 ROCM Score: +21.39

A "high flier", but fundamentally very sound. Real clean balance sheet. Earnings are on the come, and since it's so thinly traded, any above average buying volume could make this run up again, maybe, just maybe to last year's highs--30!!!

Recs

0
Member Avatar enigma616 (66.86) Submitted: 3/26/2008 10:39:10 AM : Underperform Start Price: $10.29 ROCM Score: -40.34

one of the worst picks for Jim Cramer. I don't see any upside on this stock for awhile.

Recs

0
Member Avatar uniqque2006 (< 20) Submitted: 2/29/2008 1:14:08 AM : Outperform Start Price: $10.67 ROCM Score: +34.77

Thumb up. Innovator with only product of its kind... Saves lifes and I dont see any other reason to use normal tubes that can potentially kill patients, even if they cost more. Lets hope hospitals think the same.

Recs

0
Member Avatar soho48 (92.99) Submitted: 2/5/2008 8:24:01 PM : Outperform Start Price: $11.00 ROCM Score: +27.99

Unknown and unloved, yet very important to those who stay in the hospital....

Recs

0
Member Avatar PaulNoir (< 20) Submitted: 1/21/2008 11:47:59 PM : Outperform Start Price: $10.78 ROCM Score: +22.78

Undervalued

Recs

0
Member Avatar davidpcpa (27.33) Submitted: 1/14/2008 3:26:45 PM : Outperform Start Price: $10.80 ROCM Score: +38.48

Lawsuits are almost settled, sales are ramping up, margins are expanding and the macro hospital market is in the market for a product like this.

Recs

0
Member Avatar Biotech2008 (50.00) Submitted: 1/4/2008 10:03:24 PM : Outperform Start Price: $11.15 ROCM Score: +33.39

HelicalZz @ 11.47

Recs

0
Member Avatar egenesis (85.81) Submitted: 1/1/2008 7:02:52 PM : Outperform Start Price: $11.19 ROCM Score: +37.45

While current p/e of 4 reflects big judgment against rivals, a rudimentary analysis that spreads the judgment over the years (assuming it was earned from sales) gives a p/e of 6, which is still darn good; three of the competitors acceded, 4th one, Covidian isnt a big player, so the money from that settlement unlikely to be big; one of the rivals had to agree marketing company products; this bodes well because it has other innovations in addition to the litigated catheters; the court win shows the grit and determination of the company, like David slaying the Goliaths; stock beaten down by Investors Business Daily speculators taking losses for 07; still ignored by herding Wall Street analysts; while insiders have been selling, it was at higher levels and they still have very high equity in the company; $150 mil foley catheters sell per year, almost ROCM's market cap, company may be able to charge more for its premium product.

Recs

0
Member Avatar PhDinMS (30.84) Submitted: 12/28/2007 6:33:42 PM : Outperform Start Price: $11.56 ROCM Score: +32.27

After winning some lawsuits and expanding their exposure in hospitals, the superiority of their products will finally result in great profits for ROCM

Recs

0
Member Avatar tsaro (< 20) Submitted: 9/20/2007 7:12:13 PM : Outperform Start Price: $18.98 ROCM Score: -30.92

Short-term opportunity through settlement with Covidien, plus long-term sales growth to large potential market.

Recs

0
Member Avatar sphericalbovine (< 20) Submitted: 9/1/2007 8:34:52 AM : Outperform Start Price: $15.90 ROCM Score: -16.03

ROCM will benefit from 3 things in the 1 year or so time frame. First, the benefits of the Premier and Novation contracts. Second, new medicare rules will hold hospitals financially acountable for UTI's developed under their care. Sales of their antibacterial catheters should benefit. Third, medicare is moving to more frequent replcements for external catheters. THis will beneFIT ROCM's external lines. The stock is not cheap, but the evidence for higher valuation will appear in the next year or so.

Recs

0
Member Avatar PAYLEE (53.43) Submitted: 8/8/2007 3:46:59 PM : Outperform Start Price: $14.98 ROCM Score: -6.42

I have the sudden urge to pee...

Results 1 - 20 of 52 : 1 2 3 Next »

Featured Broker Partners


Advertisement